Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD).

According to documents submitted by the company to the United States Securities and Exchange Commission (SEC), this milestone marks significant progress in the clinical development program for the candidate drug. TNX-102 SL is a proprietary sublingual formulation designed for rapid onset and to improve symptoms of major depressive disorder. The Phase II “Horizon” study is intended to evaluate the safety, tolerability, and preliminary efficacy of the drug. The successful enrollment of the first patient paves the way for further collection and analysis of clinical trial data.Major depressive disorder is a common and severe mental illness that affects millions of people worldwide. Although there are many existing therapies, there remain unmet clinical needs in terms of onset speed, tolerability, or efficacy. Tonix Pharmaceuticals is dedicated to developing innovative therapies to address this challenge.This clinical advancement is expected to inject new momentum into Tonix Pharmaceuticals’ research and development pipeline. Investors and industry observers will closely follow the subsequent research results to assess the potential of TNX-102 SL in the highly competitive antidepressant drug market.